Glyance
4
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 4 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
A Prospective, Randomized, Double-blinded, Controlled, Split-face, Non-inferiority Clinical Investigation Comparing the Safety and Performance of RefillHA Solid With Hydryalix Ultra Deep Lidocaine for the Correction of Moderate-to-severe Nasolabial Folds.
Role: lead
Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2
Role: lead
Post Market Non-Interventional Study of Safety and Performance of RefillHA Volume
Role: lead
Post Market Study of Safety and Performance of RefillHA Volume+ for Facial Soft Tissue Augmentation and Correction of Wrinkles and Folds
Role: lead
All 4 trials loaded